# EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases

> **NCT05688241** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 10 (estimated)

## Conditions studied

- EBV Lymphoma
- Post-transplant Lymphoproliferative Disease (PTLD)

## Interventions

- **DRUG:** Donor-derived ex-vivo expanded EBV Tscm CTL

## Key facts

- **NCT ID:** NCT05688241
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11
- **Primary completion:** 2031-12
- **Final completion:** 2031-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05688241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05688241, "EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT05688241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*